Group 1 - The company, 博安生物 (06955.HK), has entered into a placement agreement with UBS Group to sell a total of 38.4 million shares, representing approximately 7.17% of the total issued shares as of the announcement date [1] - The placement price is set at HKD 10.42 per share, which is a discount of about 13.88% compared to the last closing price of HKD 12.10 on the Stock Exchange [1] - The total expected proceeds from the placement are approximately HKD 400 million, with a net amount of about HKD 396 million anticipated [2] Group 2 - The company plans to allocate approximately 50% of the net proceeds for the research and development of innovative candidate products, including clinical trials for BA1106, BA1301, and BA1302, as well as non-clinical and clinical studies for BA1304 and PR201 [2] - About 20% of the net proceeds will be used for the commercialization of already launched and upcoming products [2] - Approximately 30% of the net proceeds will be allocated to supplement the company's working capital and for general corporate purposes [2]